Northwest Sued Over Cancer Vaccine Claim
Northwest Biotherapeutics, which saw its share price more than double after the biotechnology company announced approval of the world's first brain cancer vaccine, faces two purported securities class actions for allegedly...To view the full article, register now.
Already a subscriber? Click here to view full article